JP2025506487A5 - - Google Patents

Info

Publication number
JP2025506487A5
JP2025506487A5 JP2024547502A JP2024547502A JP2025506487A5 JP 2025506487 A5 JP2025506487 A5 JP 2025506487A5 JP 2024547502 A JP2024547502 A JP 2024547502A JP 2024547502 A JP2024547502 A JP 2024547502A JP 2025506487 A5 JP2025506487 A5 JP 2025506487A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
cancer
composition according
larazotide
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024547502A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025506487A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/062247 external-priority patent/WO2023154770A1/en
Publication of JP2025506487A publication Critical patent/JP2025506487A/ja
Publication of JP2025506487A5 publication Critical patent/JP2025506487A5/ja
Pending legal-status Critical Current

Links

JP2024547502A 2022-02-09 2023-02-09 Rhoキナーゼを阻害する組成物及び方法 Pending JP2025506487A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263308330P 2022-02-09 2022-02-09
US63/308,330 2022-02-09
PCT/US2023/062247 WO2023154770A1 (en) 2022-02-09 2023-02-09 Compositions and methods for inhibiting rho kinase

Publications (2)

Publication Number Publication Date
JP2025506487A JP2025506487A (ja) 2025-03-11
JP2025506487A5 true JP2025506487A5 (cg-RX-API-DMAC7.html) 2026-02-17

Family

ID=87565095

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024547502A Pending JP2025506487A (ja) 2022-02-09 2023-02-09 Rhoキナーゼを阻害する組成物及び方法

Country Status (6)

Country Link
US (1) US20250144166A1 (cg-RX-API-DMAC7.html)
EP (1) EP4475867A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025506487A (cg-RX-API-DMAC7.html)
CN (1) CN119730867A (cg-RX-API-DMAC7.html)
CA (1) CA3243960A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023154770A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118873629B (zh) * 2024-09-27 2024-12-10 北京大学口腔医学院 醋酸拉唑肽在制备促进成骨药物中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009047532A2 (en) * 2007-10-12 2009-04-16 Cancer Research Technology Limited Cancer susceptibility loci
WO2009132050A2 (en) * 2008-04-21 2009-10-29 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
JP2020507626A (ja) * 2017-02-10 2020-03-12 イノベイト バイオファーマシューティカルズ インコーポレイテッド 腸上皮の透過性と関連する疾患を治療する組成物及び方法
WO2019183036A1 (en) * 2018-03-19 2019-09-26 Innovate Biopharmaceuticals, Inc. Compositions and methods for potentiating immune checkpoint inhibitor therapy
KR20220049005A (ko) * 2019-08-16 2022-04-20 9 미터스 바이오파마, 인코포레이티드 라라조타이드 제형
AU2021255955A1 (en) * 2020-04-15 2022-11-10 Interlude Biopharma Co. Larazotide derivatives comprising d-amino acids

Similar Documents

Publication Publication Date Title
TWI846665B (zh) 用於起因於剪接異常之遺傳性疾病的醫藥組合物及治療方法
US11976334B2 (en) Inhibitor of ATR kinase for use in a method of treating a hyper-proliferative disease
ES2906227T3 (es) Potenciador de efecto antitumoral
JP6895251B2 (ja) レトロウイルスにより引き起こされる疾患を処理する為に有用な化合物
Velagapudi et al. Design and synthesis of poly (ADP-ribose) polymerase inhibitors: impact of adenosine pocket-binding motif appendage to the 3-oxo-2, 3-dihydrobenzofuran-7-carboxamide on potency and selectivity
TW200927113A (en) Qninoline derivatives for modulating DNA methylation
ES2953005T3 (es) Tratamiento para el cáncer
CN107613983A (zh) 抗肿瘤剂的副作用减轻剂
US9321759B2 (en) Methods and use of bifunctional enzyme-building clamp-shaped molecules
JP2024164126A (ja) 有機化合物
EP3590941A1 (en) Urea-substituted aromatic ring-linked dioxane-quinazoline and -linked dioxane-quinoline compounds, preparation method therefor and use thereof
WO2019011293A1 (zh) 靶向于pd-1的皂苷类化合物及其应用
US10220072B2 (en) Mesalamine for the treatment of cancer
WO2024175042A1 (zh) 药物偶联物治疗肿瘤疾病的用途及方法
Częścik et al. Evolution or revolution in colorectal cancer treatment: present and future of new therapeutic options. A narrative review
US10857113B2 (en) Bezafibrate for the treatment of cancer
CN119730867A (zh) 用于抑制rho激酶的组合物和方法
ZHANG et al. The therapeutic effect of histone deacetylase inhibitor and PD98059 conjugate on cutaneous squamous cell carcinoma
Yang et al. Review of systemic therapy options for the treatment of cholangiocarcinoma in Canada.
HK1245640B (en) Agent for alleviating adverse reaction to antitumor drug
TW202535398A (zh) 用於治療癌症之包含光學活性氮雜雙環衍生物之醫藥
KR20260058839A (ko) 5-할로우라실로 변형된 이중가닥 핵산 및 이의 암 치료에서의 용도
EP4717277A1 (en) Use of drug conjugate in treating tumor disease and method therefor
WO2014139391A1 (en) Substituted pyridine compounds as kinases inhibitors
TWI326281B (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents